Anadys shares jump on trial OK

Shares of Anadys Pharmaceuticals jumped 22 percent on the news that the FDA had approved a mid-stage study of its hepatitis C drug. The approval gives researchers a green light to begin recruiting 90 patients who will receive either a 200 mg or 400 mg dose of ANA598 or a placebo. Analysts have been closely watching the progress of Anadys' lead therapy, highlighting safety concerns after three patients dropped out of an earlier trial after developing a rash. Report

Suggested Articles

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.